Australian medical technology company Anteris Technologies (ASX:AVR) has announced the appointment of cardiologist Dr Chris Meduri as its chief medical officer.
The company has developed the DurAVR aortic replacement valve.
Dr Meduri is a recognised leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees.
He has performed first-in-US and first-in-world procedures, led enrolment in many trials and actively participated in 11 transcatheter early feasibility studies.
“With the rapid progress of the DurAVR program, the timing is now right just ahead of our planned early feasibility study to establish the role of CMO. As Chris has been working as an Advisory Board member his transition into the CMO role will be seamless," said Anteris CEO Wayne Paterson.
"Whilst still maintaining external clinical practice responsibilities, the additional time commitment from him in this new role will help us advance even further whilst adding greater credibility and profile to our product. Chris is well known and respected within the global cardiology community. We are thrilled he has agreed to be our CMO,”
As a practising clinician, Dr Meduri has performed more than 1500 TAVR (transcatheter aortic valve replacement) procedures using all currently available products, helped to build post-operative care pathways for patients and developed an app used to optimise their care.
“I am honoured to take on a broader role with the Anteris team to help deliver on its mission of delivering the world’s most durable heart valve. I look forward to collaborating with the talented team and advisory board to launch the DurAVR™ product and aid in providing a longer-lasting TAVR future for all patients,” said Dr Meduri.